Algernon Value Proposition

About our
Company

Who we are
Algernon Pharmaceuticals is a clinical stage pharmaceutical development company focused on the areas of non–alcoholic steatohepatitis (NASH), chronic kidney disease (CKD), inflammatory bowel disease (IBD) and idiopathic pulmonary fibrosis (IPF). Algernon’s key compounds were identified using a drug repurposing strategy.
Our Process
Drug repurposing is the process of discovering new therapeutic uses for existing drugs. Repurposing offers several benefits over traditional drug development including a reduction in investment and risk, shorter research periods and a longer active patent life. Algernon has protected its lead compounds with both method of use and new composition of matter patents for their derivatives and analogues.

The Algernon business model is to advance known, safe and already approved genericized drugs for new disease indications.

The Company is developing drugs for the following 4 major disease areas:

Click above to view each disease pipeline

Targeted Diseases

Algernon Pharmaceuticals has developed strong pre-clinical data that supports the advancement of 4 of its leading drug candidates into phase II trials in the areas of non–alcoholic steatohepatitis (NASH), chronic kidney disease (CKD), inflammatory bowel disease (IBD) and idiopathic pulmonary fibrosis (IPF).
Non–alcoholic Steatohepatitis
More about NASH
Chronic Kidney Disease
More about CKD
Inflammatory Bowel Disease
More about IBD
Idiopathic Pulmonary Fibrosis
More about IBD